These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32523311)

  • 61. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury.
    Tiegs G
    Z Gastroenterol; 2007 Jan; 45(1):63-70. PubMed ID: 17236122
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gut microbiota and probiotics in chronic liver diseases.
    Cesaro C; Tiso A; Del Prete A; Cariello R; Tuccillo C; Cotticelli G; Del Vecchio Blanco C; Loguercio C
    Dig Liver Dis; 2011 Jun; 43(6):431-8. PubMed ID: 21163715
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Secretory IgA in Intestinal Mucosal Secretions as an Adaptive Barrier against Microbial Cells.
    Pietrzak B; Tomela K; Olejnik-Schmidt A; Mackiewicz A; Schmidt M
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291586
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intestinal microbiota in liver disease.
    Haque TR; Barritt AS
    Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):133-42. PubMed ID: 27048904
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Glutamine Modulates Changes in Intestinal Intraepithelial γδT-Lymphocyte Expressions in Mice With Ischemia/Reperfusion Injury.
    Pai MH; Shih YM; Shih JM; Yeh CL
    Shock; 2015 Jul; 44(1):77-82. PubMed ID: 25784526
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Gut Microbiota in Intestinal and Liver Disease.
    Jones RM; Neish AS
    Annu Rev Pathol; 2021 Jan; 16():251-275. PubMed ID: 33234022
    [TBL] [Abstract][Full Text] [Related]  

  • 67. NAFLD, Helicobacter species and the intestinal microbiome.
    Castaño-Rodríguez N; Mitchell HM; Kaakoush NO
    Best Pract Res Clin Gastroenterol; 2017 Dec; 31(6):657-668. PubMed ID: 29566909
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Gut Microbiota Modulation on Intestinal Mucosal Adaptive Immunity.
    Wang L; Zhu L; Qin S
    J Immunol Res; 2019; 2019():4735040. PubMed ID: 31687412
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment.
    Ekmekciu I; von Klitzing E; Fiebiger U; Neumann C; Bacher P; Scheffold A; Bereswill S; Heimesaat MM
    Front Cell Infect Microbiol; 2017; 7():167. PubMed ID: 28529928
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Gut Microbiota and Complications of Liver Disease.
    Acharya C; Bajaj JS
    Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies.
    Frasinariu OE; Ceccarelli S; Alisi A; Moraru E; Nobili V
    Dig Liver Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23280158
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Gamma delta (γδ) T cells in cancer immunotherapy; where it comes from, where it will go?
    Deng J; Yin H
    Eur J Pharmacol; 2022 Mar; 919():174803. PubMed ID: 35131312
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interactions Between the Gut Microbiota and the Host Innate Immune Response Against Pathogens.
    Cheng HY; Ning MX; Chen DK; Ma WT
    Front Immunol; 2019; 10():607. PubMed ID: 30984184
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intestinal permeability in physiological and pathological conditions: major determinants and assessment modalities.
    Graziani C; Talocco C; De Sire R; Petito V; Lopetuso LR; Gervasoni J; Persichilli S; Franceschi F; Ojetti V; Gasbarrini A; Scaldaferri F
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):795-810. PubMed ID: 30720188
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Isolation, Characterization, and Culture of Intestinal Intraepithelial Lymphocytes.
    James OJ; Vandereyken M; Swamy M
    Methods Mol Biol; 2020; 2121():141-152. PubMed ID: 32147793
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment.
    Guo XY; Liu XJ; Hao JY
    J Dig Dis; 2020 Mar; 21(3):147-159. PubMed ID: 32040250
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Loss of gut barrier integrity triggers activation of islet-reactive T cells and autoimmune diabetes.
    Sorini C; Cosorich I; Lo Conte M; De Giorgi L; Facciotti F; Lucianò R; Rocchi M; Ferrarese R; Sanvito F; Canducci F; Falcone M
    Proc Natl Acad Sci U S A; 2019 Jul; 116(30):15140-15149. PubMed ID: 31182588
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sodium selenite ameliorates dextran sulfate sodium-induced chronic colitis in mice by decreasing Th1, Th17, and γδT and increasing CD4(+)CD25(+) regulatory T-cell responses.
    Sang LX; Chang B; Zhu JF; Yang FL; Li Y; Jiang XF; Wang DN; Lu CL; Sun X
    World J Gastroenterol; 2017 Jun; 23(21):3850-3863. PubMed ID: 28638225
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent arthritis.
    Rogier R; Ederveen THA; Boekhorst J; Wopereis H; Scher JU; Manasson J; Frambach SJCM; Knol J; Garssen J; van der Kraan PM; Koenders MI; van den Berg WB; van Hijum SAFT; Abdollahi-Roodsaz S
    Microbiome; 2017 Jun; 5(1):63. PubMed ID: 28645307
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD.
    Pierantonelli I; Rychlicki C; Agostinelli L; Giordano DM; Gaggini M; Fraumene C; Saponaro C; Manghina V; Sartini L; Mingarelli E; Pinto C; Buzzigoli E; Trozzi L; Giordano A; Marzioni M; Minicis S; Uzzau S; Cinti S; Gastaldelli A; Svegliati-Baroni G
    Sci Rep; 2017 Sep; 7(1):12200. PubMed ID: 28939830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.